547 related articles for article (PubMed ID: 9247787)
1. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
Kotaki M; Uday K; Henriquez M; Blum S; Dave M
Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
[No Abstract] [Full Text] [Related]
2. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients.
Drüeke TB; Bárány P; Cazzola M; Eschbach JW; Grützmacher P; Kaltwasser JP; Macdougall IC; Pippard MJ; Shaldon S; van Wyck D
Clin Nephrol; 1997 Jul; 48(1):1-8. PubMed ID: 9247771
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
Wingard RL; Parker RA; Ismail N; Hakim RM
Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
[TBL] [Abstract][Full Text] [Related]
5. Iron management during recombinant human erythropoietin therapy.
Van Wyck DB
Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
[TBL] [Abstract][Full Text] [Related]
6. Human recombinant erythropoietin (rHuEPO) in the treatment of anemia in patients with chronic renal failure (CRF): experience with a group of patients on chronic haemodialysis treatment.
Ramírez B; Flores A; Pérez F; Córdoba C; García L; Vázquez G
Transplant Proc; 1991 Apr; 23(2):1833-4. PubMed ID: 2053170
[No Abstract] [Full Text] [Related]
7. Effect of recombinant human erythropoietin on iron balance in maintenance hemodialysis: theoretical considerations, clinical experience and consequences.
Grützmacher P; Tsobanelis T; Roth P; Werner E; Vlachojannis J; Kaltwasser J; Kurz P; Scheuermann EH; Schoeppe W
Clin Nephrol; 1992; 38 Suppl 1():S92-7. PubMed ID: 1295714
[TBL] [Abstract][Full Text] [Related]
8. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
9. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure.
Hotta T; Ogawa H; Saito A; Ito A
Int J Hematol; 1991 Jun; 54(3):195-200. PubMed ID: 1747454
[TBL] [Abstract][Full Text] [Related]
10. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
Johnson CA; Rosowski E; Zimmerman SW
Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
12. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
13. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
von Appen K; Klinkmann H
Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
[No Abstract] [Full Text] [Related]
14. Oral iron absorption in hemodialysis patients treated with erythropoietin.
Donnelly SM; Posen GA; Ali MA
Clin Invest Med; 1991 Aug; 14(4):271-6. PubMed ID: 1782724
[TBL] [Abstract][Full Text] [Related]
15. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
Van Wyck DB
Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
[TBL] [Abstract][Full Text] [Related]
16. [The use of recombinant erythropoietin with patients on programmed hemodialysis].
Rozental' RL; Zezina LIu; Spudass AV
Ter Arkh; 1991; 63(12):110-3. PubMed ID: 1803587
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human erythropoietin on hematopoietic progenitors of chronic hemodialysis patients in vitro and in vivo.
Hino M; Miyazono K; Urabe A; Takaku F
Int J Cell Cloning; 1989 Jul; 7(4):257-63. PubMed ID: 2768843
[TBL] [Abstract][Full Text] [Related]
18. [Anemia in chronic hemodialysis; comparative value of iron therapy administered by oral and intravenous routes].
Ducros J; Benas P; Salvadori JM; Olmer M
J Urol Nephrol (Paris); 1977 Sep; 83(9):735-8. PubMed ID: 926237
[No Abstract] [Full Text] [Related]
19. Effects of erythropoietin on strength and functional status of patients on hemodialysis.
Guthrie M; Cardenas D; Eschbach JW; Haley NR; Robertson HT; Evans RW
Clin Nephrol; 1993 Feb; 39(2):97-102. PubMed ID: 8448925
[TBL] [Abstract][Full Text] [Related]
20. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
Ahluwalia N; Skikne BS; Savin V; Chonko A
Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
